MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 11..20 of 101 - per page Previous page Next page
Order by
BIOIBERICA would extend the right to use its CTD dossier for registration of Cartisorb® (Glucosamine Sulfate sachets) as a branded generic drug (to be marketed under Cartisorb® brand name or other brand name) on a local level. More
Capsaicin, the active ingredient found in red-hot peppers, is used mainly for the relief of chronic pain of rheumatoid arthritis and osteoarthritis More
Locally applied and locally acting NSAID Matrix Patch containing 140 mg Diclofenac Sodium More
Novel Dual Chamber Dispenser with polycarbonate and stainless steel components for accurate Rx dosing. More
25mg dosage strenght for the OTC market More
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
Identification and use of RAR antagonists to induce bone and cartilage formation More
The matrix consists of two polysaccharides, xanthan and locus More
A diagnostic and therapeutic secreted target protein that is upregulated in a subset of human patients with Osteoarthritis. It is a strong regulatory candidate for the transformation of maintenance chondrocytes into digestive aggravators of OA. More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
Displaying 11..20 of 101 - per page Previous page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us